
CervoMed Inc (CRVO) Stock Forecast & Price Target
CervoMed Inc (CRVO) Analyst Ratings
Bulls say
CervoMed Inc's stock outlook is supported by favorable data from the Phase 2b RewinD-LB trial for its product candidate, Neflamapimod, particularly highlighted by a 64% risk reduction (p=0.0001) among patients with minimal evidence of Alzheimer's disease co-pathology. The trial's 32-week open-label extension produced significant results, showcasing Neflamapimod's potential to treat synaptic dysfunction associated with age-related neurologic disorders. Additionally, the contrasting results of placebo recipients, who exhibited a mean increase in biomarkers, further underscore the effectiveness of Neflamapimod in this patient population.
Bears say
CervoMed Inc faces multiple significant risks that contribute to a negative outlook on its stock, including the potential inability to establish a clinically acceptable development pathway for its lead product candidate, neflamapimod, in treating dementia with Lewy bodies (DLB). Additionally, the company confronts challenges related to the generation of positive data from pivotal clinical trials, which could hinder regulatory approval and market uptake, alongside risk of dilution in the medium term. The valuation methodology applied, incorporating a 40% probability of approval for neflamapimod, coupled with a high discount rate of 12%, reflects substantial uncertainty regarding the product's future success in the market.
This aggregate rating is based on analysts' research of CervoMed Inc and is not a guaranteed prediction by Public.com or investment advice.
CervoMed Inc (CRVO) Analyst Forecast & Price Prediction
Start investing in CervoMed Inc (CRVO)
Order type
Buy in
Order amount
Est. shares
0 shares